280 related articles for article (PubMed ID: 19078924)
1. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.
Bansal N; Yendluri V; Wenham RM
Cancer Control; 2009 Jan; 16(1):8-13. PubMed ID: 19078924
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
Lax SF
Virchows Arch; 2004 Mar; 444(3):213-23. PubMed ID: 14747944
[TBL] [Abstract][Full Text] [Related]
3. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract][Full Text] [Related]
4. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic targets in endometrial cancer.
Dedes KJ; Wetterskog D; Ashworth A; Kaye SB; Reis-Filho JS
Nat Rev Clin Oncol; 2011 May; 8(5):261-71. PubMed ID: 21221135
[TBL] [Abstract][Full Text] [Related]
6. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
7. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract][Full Text] [Related]
8. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats.
Samuelson E; Hedberg C; Nilsson S; Behboudi A
Endocr Relat Cancer; 2009 Mar; 16(1):99-111. PubMed ID: 19075038
[TBL] [Abstract][Full Text] [Related]
10. FGFR2 as a molecular target in endometrial cancer.
Byron SA; Pollock PM
Future Oncol; 2009 Feb; 5(1):27-32. PubMed ID: 19243295
[TBL] [Abstract][Full Text] [Related]
11. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets and targeted therapeutics in endometrial cancer.
Weigelt B; Banerjee S
Curr Opin Oncol; 2012 Sep; 24(5):554-63. PubMed ID: 22581357
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.
Llobet D; Pallares J; Yeramian A; Santacana M; Eritja N; Velasco A; Dolcet X; Matias-Guiu X
J Clin Pathol; 2009 Sep; 62(9):777-85. PubMed ID: 18977806
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathology of endometrial hyperplasia and carcinoma.
Matias-Guiu X; Catasus L; Bussaglia E; Lagarda H; Garcia A; Pons C; Muñoz J; Argüelles R; Machin P; Prat J
Hum Pathol; 2001 Jun; 32(6):569-77. PubMed ID: 11431710
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of endometrial cancer.
Berchuck A; Boyd J
Cancer; 1995 Nov; 76(10 Suppl):2034-40. PubMed ID: 8634996
[TBL] [Abstract][Full Text] [Related]
17. Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Gadducci A; Tana R; Cosio S; Fanucchi A; Genazzani AR
Gynecol Endocrinol; 2008 May; 24(5):239-49. PubMed ID: 18569027
[TBL] [Abstract][Full Text] [Related]
18. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
[TBL] [Abstract][Full Text] [Related]
20. Targeting fibroblast growth factor pathways in endometrial cancer.
Winterhoff B; Konecny GE
Curr Probl Cancer; 2017; 41(1):37-47. PubMed ID: 28041631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
